Alto Neuroscience, Inc. (ANRO): Capital Expenditures
$24.0K
Year ended 2025-12-31
$556.0K
Trailing 12 months to 2026-06-30
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.0K | -98.8% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $2.08M | +341.5% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $470.0K | n/a | 2025-03-20, From 2023-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $24.0K | -98.8% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $0 | -100.0% |
| Fortress Biotech, Inc. (FBIO) | 2024-12-31 | $0 | -100.0% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $105.0K | +483.3% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $1.74M | +55.5% |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $12.0K | -65.7% |
| PepGen Inc. (PEPG) | 2025-12-31 | $264.0K | -46.9% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $79.0K | n/a |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $50.0K | -94.5% |
Compare ANRO, LXRX, FBIO, BNTC side by side · Screen every company in Pharmaceutical Preparations ↗